Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery
NCT: NCT07576517 · NOT_YET_RECRUITING
Brief Summary
Neurocognitive complications, mainly delirium and neurocognitive disorders, are common cerebral complications in older patients after surgery and associated with worse outcomes. In previous studies, perioperative use of dexmedetomidine-esketamine combination improved analgesia and sleep quality after surgery. Perioperative use of transcranial direct current stimulation (tDCS) also improved sleep quality and reduced delirium occurrence early after surgery. This 2×2 factorial trial is designed to investigate the effects of perioperative dexmedetomidine-esketamine combination and tDCS on early postoperative neurocognitive recovery and delirium occurrence in older patients.
Frequently Asked Questions
What is Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery?
Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery is a clinical trial registered under NCT07576517. Current status: NOT_YET_RECRUITING.
What is the status of NCT07576517?
The current status of NCT07576517 (Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery) is: NOT_YET_RECRUITING.
When did Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery start?
Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.